Robert J. Ternansky, Ph.D. recently joined ALSP and brings to the Company extensive experience in medicinal chemistry, especially in the design and development of small molecule protease inhibitors He is also currently Vice President, Chemistry of Attenuon, in San Diego, CA and Lecturer at the University of California, San Diego. Dr. Ternansky was previously the Director of Medicinal Chemistry at IDUN Pharmaceuticals, Inc. in San Diego where he co-invented a lead series of caspase inhibitors for the prevention of apoptotic cell death. Prior to his work at IDUN, Dr. Ternansky held the position of Associate Director of Inflammation at La Jolla Pharmaceuticals, Inc., where he led the analytical team on the pre-clinical development of LJP-394, a toleragen for the treatment of lupus, currently in Phase III trials. Prior to joining La Jolla Pharmaceuticals, Dr. Ternansky was a Research Scientist and Team Leader at Eli Lilly and Co., where he invented LY193239,
the first pyrazolidinone antibacterial agent to be developed for clinical investigation. He was also a member of the pre-clinical discovery/development team for loracarbef (Lorabid), the first marketed 1-carbacephalosporin antibacterial agent. Finally, Dr. Ternansky also invented trovirdine, a NNRT inhibitor of HIV-1 RT, which is currently in Phase III trials for the treatment of HIV infection. Dr. Ternansky received his Ph.D. in Synthetic Organic Chemistry from The Ohio State University and completed his post-doctoral training with Professor Paul A. Wender at Stanford University.
